Research on India_Healthcare Sector in India Monthly Update_May 2012

Healthcare Sector in India Monthly Update

May 2012

Top Story Cipla slashes price of cancer drugs to surprising levels Cipla Ltd. that has been manufacturing the generic version of Bayer invented cancer drug Nexavar, like Natco Pharma, has taken the price competition to a different level altogether. Natco’s reduction in price of generic version of the drug to INR 8,800 has led Cipla to slash down the price to INR 6,600 per month. Not only has the price of eneric version of Nexavar been reduced, Cipla has reduced price of another cancer gdrug Soranib from INR 6,990 to INR 1,776. The price competition has led the fall in price of Bayer manufactured Nexavar from INR 0.28 mn to the present standard making cancer treatment largely affordable for the masses. News Update

General Intas to foray into global hospital business Ahmedabad based Intas Pharmaceuticals has geared itself to diversify into hospital business. It plans to invest close to INR 5.30 bn to buy marketing companies in developed countries that will enable a strong foundation to its global hospital business. The company is pursuing to acquire marketing set‐up and hospital licenses in the US, Canada and Europe. The company however is not losing focus in its pharmaceuticals business. It has plans of taking the company from its current 12th position to among top 5 by 2015 in India. Apart from India, Intas has strong presence in USA and Europe’s pharmaceutical market. Lupin Ltd. invests in preclinical software solution developed by Instem Mumbai based Lupin Ltd. has purchased Provantis (R) preclinical software solution from Conshohocken, Pennsylvania based Instem. The software will be installed at Lupin’s R&D centre Lupin Research Park in Pune. Instem is a leading provider of laboratory data and information management solutions for drug safety studies that boasts of an industry ex almost 30 years.

perience of

The software module consists of an Integrated Inlife Toxicology and Pathology modules along with a number of Clinical Pathology interfaces. The software comes with a range of Professional Services with validation and training adaptations to

Healthcare – Monthly Update

ensure easy implementation of the software. Instem's Data Import module will also ensure speedy entry of clinical pathology data. GSK healthcare launches cola flavoured Eno GlaxoSmithKline Consumer Healthcare Ltd. has recently launched a new Cola flavour of its highest selling antacid brand Eno. The company has been continuing its efforts to constantly innovate its products without compromising on the respective medicinal significance. The innovation was carried out keeping in mind the prevalence in use of Cola to deal with acidity problems. Eno enjoys the second highest market in India after Brazil among all the 40 countries it is available in. Among the 3 formats of antacids liquids, tablets and powders‐ the powder category is estimated to be of INR 0.1 bn of which GSK’s Eno occupies 98% of the market share. Phase III clinical trial of new male birth control procedure underway in India India is currently conducting advanced stage clinical trials of a new birth control treatment for men. The procedure is being developed by the Male Contraception Information Project and is called "Reversible Inhibition of Sperm Under Guidance” (RISUG). The procedure is being touted as a 100% effective remedy that can be the uture of contraception with benefits of being relatively uninvasive and completely freversible. The procedure will be a convenient solution in comparison to vasectomy. It will require injecting a polymer gel called "Vasalgel" directly into the vas deferens that will coat the walls of the duct and kills sperm as they go by. The product is expected to be launched in US market by 2015. SOHM recognized as “The Most Emerging Company in the Recent Past” Gujarat based SOHM India Pvt. Ltd. an Indian subsidiary of N. America based SOHM Inc. received “The Most Emerging Company in the Recent Past” at the 30th All India Conference of National Integrated Medical Association. The company has been recognized for its efforts by the Ministry of Health and Family Welfare; Gujarat State Tourism; Central Council of Indian Medicine, New Delhi and Food & Drug Administration, Gujarat. SOHM is a global generic pharmaceutical manufacturer, developer and marketer which established itself as the fastest growing Generic Pharmaceutical company recently. The company is a manufacturer of a vast range of pharmaceutical products covering almost all therapeutic segments.


Philips launches new equipments for India market Bangalore based Philips Innovation Centre (PIC) has developed two new portable ultrasound equipments under the brand name of ClearVue. Both the equipments integrate active array technology that offers optimal resolution of image with added advantage of lowest power consumption. Also for superior care in disease anagement Philips has introduced products in its Intelli‐Hospital product range and m

an e‐ICU. Philips is increasingly focusing on healthcare technologies with the motto “in India, for India” and is doing away with the trend of selling low cost US products in Indian market. Keyhole surgery can cure diabetes within a day The latest innovation in curing type II diabetes is the keyhole surgery. The International Diabetic Federation (IDF) has also recently recognized the procedure as a cure for the disease. The surgery cures diabetes by removal of excess fat from the tomach through keyhole surgery. The procedure has been found to be so effective, sthat patients become normal within one day after the surgery. The procedure has registered a success rate of 92% and can be carried out on a diabetic patient whether normal or obese. The procedure costs between INR 0.3 mn to INR 0.35 mn. Narayana Hrudayalaya adopts cloud based HIS for effective hospital management HCL Infosystems has recently struck a deal with Narayana Hrudayalaya as its strategic technology partner for a 5 year term. The IT Company will be responsible for nstalling and implementing cloud based hospital information system (HIS) in the ifollowing 3 months in all the 22 Narayana Hrudayalaya hospitals. The Infrastructure as a Service (IaaS) solution has already been installed in Bangalore, Ahmedabad, Jamshedpur and Jaipur hospitals. The installation of the service is expected to reduce the hospitals operation cost by about 20% and simultaneously increase the efficiency level. Dr. Reddy’s Lansoprazole capsule available in US market in OTC segment Dr. Reddy’s Laboratories has launched the Lansoprazole capsule in the over the counter segment. Dr. Reddy’s launched the capsule this month after receiving the ANDA approval by the United States Food & Drug Administration (USFDA). The capsule is known to prevent acidity that can subsequently lead to heart burn. The capsule is available in 15 mg strength in 14, 28 and 42 count pack size.


The product is a bioequivalent version of the Novartis Prevacid 24 HR capsule that had received prescription to OTC switch approval by the FDA in Mar 2009 with 3 year exclusivity. Venus Remedies antibiotic acquires a patent for its new antibiotic Haryana based Venus Remedies Ltd. has been successful in obtaining its first patent for an antibiotic combination of carbapenem and aminoglycoside. This patent was eceived from CIPRO (Companies and Intellectual Property Registration Office), South rAfrica. The company has till now more than 80 patented products to its credit. This antibiotic combination is a treatment for bacterial/ multi‐bacterial infections for all age groups including new born, children and immuno‐compromised patients. The combination is effective for children as it a low dose medication with low propensity of side effects. Venus’s success in formulation of the antibiotic is solely for the dedicated research carried out by Venus Medicine Research Centre (VMRC) that is endeavouring to develop medications to eradicate the most fatal diseases in the world. Glenmark’s drug Revamilast to enter phase III clinical trial soon Mumbai based Glenmark Pharmaceuticals inflammatory disorder treatment drug Revamilast will enter the 3rd phase of clinical trial in USA, UK and India very soon. The drug is targeted for the relief of disorders like asthma and rheumatoid arthritis. The molecule had successfully completed its pre clinical and phase I trials that had been onducted in Britain and is expecting Phase‐II b data in rheumatoid arthritis by March c2013 and clinical trial data for asthma by the middle of 2013. Glenmark also plans to file an Investigational New Drug application (IND) for evamilast in USA within the 3Ra

rd quarter of FY 2012. Glenmark has invested a huge mount in R&D in the recent past for development of innovative and effective drugs. Ranbaxy acquires patent right for Absorica Ranbaxy has acquired a patent protection from U.S. Food and Drug Administration (FDA) for the novel acne medication isotretinoin Absorica. The formulation had been developed by Canada based Cipher Pharmaceuticals Inc. and will be launched by Ranbaxy Laboratories' wholly owned subsidiary Ranbaxy Laboratories Inc. (RLI) in SA in the 4th quarter of FY 2012. Ranbaxy would be liable to pay Cipher royalties on U

its net sales of the severe recalcitrant nodular acne medication. The medication had been developed jointly by the Scientific Affairs team at Cipher nd Cipher’s partner Galephar Pharmaceutical Research. The dermatology segment of anbaxy is expected to get a boost with its latest patented innovation. aR


Parry ties up with Euro RSCG for creation of its digital platform Chennai based Parry Nutraceuticals a division of the Murugappa group has entrusted Bangalore based Euro RSCG 4D Matrix for creation of a data digital presence for their nutritional food supplements. The data digitalization will be carried out through earch engine optimization (SEO), pay per click (PPC) and other social media services sby Euro RSCG. arry’s nutraceutical products are marketed to as many as 38 countries and the igital platform will help the company in realizing its e‐commerce plans. Pd News Update

Regulatory Tamil Nadu state government takes initiative to set up vaccine complex Tamil Nadu state government will soon have an integrated vaccine complex that has already been approved by the Prime Minister and his cabinet. INR 5.9 bn is being invested to develop the HLL Biotech Ltd. HLL Biotech will be a wholly owned subsidiary of HLL Lifecare Ltd. ‐ the Mini Ratna Company of Govt. of India under the Ministry of Health & Family Welfare. The first phase of the vaccine complex will be built in Kanchipuram district which is scheduled to be completed in 36 months

.

The plant will produce vaccinations for DPT, hepatitis B, BCG, measles, rabies, Japanese encephalitis and haemophilus influenza B among other diseases. It will also focus on other revolutionary vaccines in multi‐bacterial and multi‐viral areas to arrest epidemic or pandemic situations, if any. After completion of the project, the unit is estimated to manufacture 585 mn doses of vaccinations annually. IPEC Foundation sets its footprint in India The International Pharmaceutical Excipients Council (IPEC) Foundation is in plans to set up IPEC India that will help Indian pharmaceutical excipient manufacturers to voice their concerns and opinions in a global platform. It is being expected that the PEC India head office will be located in Mumbai and headed by Mr. Ajit Singh, Ichairman of ACG Worldwide and start Indian operation by June 2012. The IPEC India will also serve as trade association related to excipients that will provide a platform to the product exporters to discuss about the issues decelerating he market growth and other industry oriented issues relating to functioning of egulation for ensuring safe use of drug and patient safety. tr MBP adoption by Union government to bring relief to pharmaceutical manufacturers India is currently in need of scaling up the process of introduction of new chemical entities which require heavy investments. The industry specialists opine that


introduction of Market Based Pricing (MBP) will provide enough support to the Indian pharma industry operators. The Union government’s decision on National Pharmaceutical Pricing Policy (NPPP) for adoption of the MBP is long awaited. India’s rowing potential in development of drugs for almost every therapeutic area like its gwestern counterpart, can be supported only by adoption of the MBP. Presently Indian drug prices are low that is harmful for the growth and stability of the ndian pharma companies and hence is in need of a pricing strategy that would boost he industry’s growth process. It ABLE puts forth recommendations for biotech industry betterment Association of Biotech Led Enterprises (ABLE), the not for profit organization and representative of the biotechnology industry of India has voiced its aim to the Department of Biotechnology (DBT) of treading India into a growth path that it should follow. ABLE has put forward its recommendation of allocation of INR 50 bn funding for soft loans at 4% to 6% with 2 years freeze period and 5 years tax holiday from date of commercialization, larger Special Economic Zones (SEZs) meant for biologics, including biotech drugs under the free medicines scheme, preference to 100% indigenously manufactured biotech drugs for various government schemes, simplified rocedures for obtaining various approvals, including biotech medicines like insulin,

. pmonoclonal antibodies (mAbs) and recombinant proteins in the list of essential drugs India is progressively gaining a leading position in the area of biotechnology through its worldwide exports and has portrayed the ability to give tough competition to USA, uropean Union and Japan in the near future. E News Update

Expansion Plans Abott enters into agreement with Biocon and Syngene for nutrition products business US based Abott Laboratories has entered into an alliance with Bangalore based Biocon Ltd. to increase its nutritive product portfolio in India. Although Abott is already operative in nutrition product segment with products like PediaSure and Similac for children and diabetic supplement Glucerna, it plans to boost its presence


in the segment through the tie up. Abott has entered into an agreement with Biocon’s contract research unit Syngene International Ltd. by which Abott will set up in India its first R&D center in Bangalore that will be equipped with more than 50 researchers and scientists. The R&D unit is scheduled to start functioning in June 2012.

NSF–DBA and Semler collaboration to raise the quality of Indian pharmaceutical market UK based NSF–DBA, the USA based National Science Foundation (NSF) International Health Sciences Company has signed an agreement with Bangalore based Semler esearch Center Pvt. Ltd. (SRC) for development of pharmaceutical training, auditing, Rconsulting and testing services throughout India. Expansion of the programme will provide global and Indian pharmaceutical companies local access to essential services that will enhance the safety level and quality of pharmaceutical products. The agreement also opened up the opportunity for provision of services like onsite Good Manufacturing Practices (GMP) remediation and validation, training to international standards for pharmaceuticals, medical devices and dietary supplements, clinical services, bioanalytical services and formulation and process and analytical development in India. MDI to raise standard of hospital laboratory service in India Germany based clinical laboratory Medizinisch Diagnostiche Institute (MDI) plans to build 1000 sample collection centres and a dynamic logistics network to transport samples across the country. The company has decided to invest INR 0.5 bn in the ubsequent two years for installation of machines and web based software in as many sas 25 hospital laboratories across the country. MDI has also made elaborate plans to provide international standard service inclusive of tests that are not available in India as yet. MDI has also planned to train doctors and technicians of hospitals that have been upgraded by MDI in handling the advanced laboratory equipments and software in Germany. Vini Cosmetics to add food supplements to its product line Vini Cosmetics that operates in the personal care category will soon foray into utraceuticals segment by end of 2012. The company has planned to invest INR 0.4 bn nto enter into this business segment. Although the company had planned to enter the segment in 2010 through a joint venture with a Japanese firm, it suffered a set back due to back out of its partner. However, now the company will realize it’s much planned business diversification by investing the amount solely and launch products by the end of 2012. Piramal acquires DRG for INR 34 bn Piramal Healthcare Ltd. will penetrate into healthcare database and consulting services industry through its intended acquisition of US based health information company Decision Resources Group. Piramal’s decision to adopt a diversified business strategy has led to the company in investing INR 34 bn for buying Decision Resources Group (DRG).


Piramal Healthcare Ltd. will soon be renamed as Piramal Enterprises Ltd. to give shape to its diversified business approach. Diversifying from its drugs business, it has invested in stake purchase of mobile phone operator Vodafone India, purchased a

iously under Germany based Bayer AG, has presence in pected to soon enter defense and security business sectors.

R&D firm that was prevfinancial services and is ex Nestor to launch new facilities in Rajasthan and Nigeria Delhi based Nestor Pharmaceuticals will be setting up a new manufacturing facilities in Rajasthan and Nigeria. The company is investing INR 0.2‐ 0.25 bn for the Nigeria facility that will be commissioned in Nov 2013 while the Rajasthan facility will be nitiated in 2014 with an investment of INR 1.5 bn. The huge investment will be raised iin house as well as through loans. In order to strengthen its presence in India, Nestor has plans of establishing its 4th facility in Rajasthan in compliance with the US FDA norms. The company already has manufacturing unit in UK and in India has its facilities in Faridabad, Hyderabad and oa of which the Faridabad facility has been built in compliance with WHO norms. aG Industry Expert Speak Lupin Ltd. i preclinical software solu ion developed by Instem invests n t Dr. Rajender Kamboj, President, Novel Drug Discovery & Development, Lupin “We were looking for a world‐class solution to support the automation of our laboratory processes, further improve productivity and ensure GLP compliance for Lupin's core Novel Drug Discovery & Development research programs. Following a thorough competitive review, we are satisfied that Provantis is the right solution to h elp us meet these needs."

GSK healthcare launches cola flavoured Eno Peshwa Acharya, Chief Marketing Officer & Director, Globacom “Young consumers in the age group of 14‐30 years are familiar with the Cola flavour and the brand has struck a chord on that positioning. This will help the brand stay top of mind among new users too. They are changing consumer perception about Eno as a etter option over carbonated drinks to kill acidity. To my knowledge, Colas infact rigger acidity, thus, it is an intelligent move to push Eno’s consumption.” bt Philips launches new equipments for India market Wido Menhardt, Head, Philips Innovation Campus (PIC) “The launch of ClearVue is testimony to Philips' commitment to bringing leading‐edge technology innovations developed and suited to Indian conditions and which address the key needs of the India market.”


Narayana Hrudayalaya adopts cloud based HIS for effective hospital management Harsh Chitale, Chief Executive Officer, HCL Infosystems “In this uncertain market, sometimes there are low growths and sometimes high growth. But one needs to be prepared for peak growth and for that you need capacity. In these difficult times, when businesses need to lower their capex, cloud is the best s olution for them”

Ranbaxy cquires atent right for Absorica Venkat Krishnan, Senior Vice President & Regional Director, Americas, Ranbaxy “We are thrilled to make Absorica available as a valuable option for the dermatologists and patients who need treatment for severe recalcitrant nodular acne. Absorica is a critical milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy's specialized dermatology sales force”

a p

Association of Biotech Led Enterprises (ABLE) puts forth recommendations for biotech industry betterment Kiran Mazumdar Shaw, Executive committee member, ABLE “Biomanufacturing is a capital intensive activity where infrastructure costs are high. Biosimilars is an opportunity that India cannot afford to miss. Many countries like Korea, Malaysia, Singapore, Turkey, Taiwan, Turkey and Argentina are finalising their guidelines for biosimilars. South Korea is actively expanding its world‐class clinical trials and production infrastructure, cultivating bio‐specialized manpower, building R&D, legal and system support strategies. India too should come out with its biosimilar policy and encourage bio‐manufacturing in a big way. We are appreciative f the Indian government asking the Industry for recommendations.” o Transactions (March 2012 – May 2012)

Date Buyer Target Deal Size (INR mn)

% stake Deal Status Type of

Transaction

16th May 2012

Piramal Healthcare Ltd.

Decision Resources Group

34000 N.A. Planned M&A

16th May 2012 Tano Capital

Shilpa Medicare Ltd. 100 N.A. Completed Private Equity


26th Apr 2012

Sterile Arcolab Ltd.

Star Drugs’ and Research Lab

Ltd. 1250 100% Completed M&A

2 r 5th Ap2012

ChrysCapital Intas

Pharmaceuticals 3000

Above 15%

Planned Private Equity

2 nd Apr2012

Advent International

Corp.

Care Hospitals Pvt. Ltd. 5600 N.A. Completed Private Equity

29th Mar 2012

C arlyle Groupand

TPG Capital India

Fortis Healthcare India

Ltd 12,993.1 15‐20% Planned Private Equity

27 r th Ma2012 CX Partners Sutures India 2000 40 Planned Private Equity

22nd Mar 2012

International Finance

Corporation SRL Diagnostics 1250 N.A. Planned Private Equity

19 r th Ma2012

International Finance

Corporation

Apollo Hospitals Enterprises Limited

3042 N.A. Planned Private Equity

15th Mar 2012

Government of Singapore Investment Corporation

(GIC)

Vasan Healthcare

5063.85 N.A. Completed Private Equity

14th Mar 2012

TVS Capital and

ePlanet Capital

Medfort Hospitals 125 N.A. Completed Private Equity

11th Mar 2012

Omzest Nova Medical N.A. 12.5 Completed M&A


Annual Financial Results – Revenue (INR mn) – Major Healthcare Companies

Companies FY ’09 FY ’10 FY ’11 FY’ 12

Abott India Ltd. 7,822.70 9,406.60 14,772.4 1 6,050.1

Ajanta Pharma Ltd. 3,493.40 4,091.40 5,048.70 6,713.8

Alembic Pharmaceuticals Ltd. 1 1,190.28 1 1,399.17 2,007.84 14,623.5

Amrutanjan Health Care Ltd. 906.73 897.79 1,054.09 1,150.23

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50 .7 ,899

Cipla Ltd. 52,876.20 56,704.00 6 3,850.70 N.A.

Claris Lifesciences Ltd. 7,435.30 7,523.40 7,387.7 7,624.6

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0

Divi's Laboratories Ltd. 11,849.50 9,499.20 13,137.00 18,585.9

Dr. Reddy’s Laboratories (DRL) 69,441.00 70,277.00 74,693.00 96,737.4

Elder Pharmaceuticals Ltd. 6,242.30 7,284.10 9,648.50 13 .9 ,237

FDC Ltd. 5,909.00 6,340.10 7,103.30 N.A.

Fresenius Kabi Oncology Ltd. 3,257.20 4,884.80 5,255.60 N.A.

GlaxosmithKline CHeathcare ltd.

onsumer 19,757.6 23,693.3 27,688.6 28 .3 ,857

GlaxoSmithKline Pharmaceuticals Ltd. 19,179.80 21,608.50 23,893.4 N.A.

Glenmark Pharmaceuticals Ltd.

21,241.20 25,291.30 29,490.70 4 0,206.4

Hikal Ltd. 5,728.70 5,389.50 5,023.00 7,078.2

Intas Pharmaceuticals Ltd. 11,266.20 16,172.30 17,541.7 N.A.

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5


Lupin Ltd. 38,508.30 48,318.10 57,851.90 7 0,829.1

Morepen Laboratories Ltd. 1,854.80 2,121.80 2,293.40 2,810.0

Nestle India Ltd. 51,395.5 62,609.4 74,994.6 7 7,409.0

Panacea Biotec Ltd. 7,921.80 9,0 0 66.7 11,573.50 6,978.0

Pfizer Ltd. 7944.1* N.A. 9,326.10 10,173.0

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Plethico Pharmaceuticals Ltd. 12,459.00 15,121.10 16,413.8 16,651.2

Ranbaxy Laboratories Ltd. 75,970.40 89,607.70 101,614.1 117,1 53.2

Strides Arcolab Ltd 13,101.6 16,958.4 25,245.2 25,645.1

Sun Pharmaceuticals Industries Ltd.

42,723.00 38,086.30 57,214.30 80,056.6

Torrent Pharmaceuticals Ltd 16,306.60 19,160.40 22,264.80 2 6,959.2

Twilight Litaka Pharma Ltd. 3,708.40 4 ,924.10 6 ,709.20 7,026.3

Vimta Labs Ltd 8 16.032 8 68.02 957.01 8 98.06

Vista Pharmaceuticals 18.231 8.014 56.745 N.A.

Wockhardt Ltd. 3 ,6294.4* 36, 0 477.6 37, 50 633. 46 .0 ,138

Zandu Realty Ltd. 877.46 N.A. N.A. N.A.

Quarterly Financial Results – Revenue (INR mn) – Major Healthcare Companies

Companies AprJun 2011

JulSep 2011

OctDec 2011

JanMar 2012

Abott India Ltd. 3,514.20 3,9 0 68.9 4,102.7 3,664.4

Ajanta Pharma Ltd. 1,273.10 N.A. 1,639.00 2,450.5


Alembic Pharmaceuticals Ltd. 3,432.7 3,969.6 3,813.3 3, 9 407.

Amrutanjan Health Care Ltd. N.A. N.A. 363.639 N.A.

Biocon Ltd. 4,416.80 5,084.40 5,171.90 6,115.0

Cadila Healthcare Ltd. 11,735.10 12 0 ,196.4 13,524.60 13 .6 ,443

Cipla Ltd. 15,91 4.20 N.A. 1 7,580.00 N.A


Dabur India Ltd. 12,045.80 12, 0 623.3 14,526.80 1,3636

Divi's Laboratories Ltd. 3,585.50 N.A. 4,174.20 7,180.4

Dr. Reddy’s Laboratories (DRL) 19,783.00 2 2,678.00 2 7,692.00 26,584.5

Elder Pharmaceuticals Ltd. 2 ,996.60 3,3 0 10.8 3,431.2 3, 9 453.

FDC Limited 1,823.2 N.A. 1,636.6 N.A.

Fresenius Kabi Oncology Ltd. N.A. N.A. 1 ,283.20 N.A.

Glaxosmithkline Consumer Healthcare Ltd. 6,533.8 7,200.7 6,854.0 8, 7 608.

GlaxoSmithKline Pharmaceuticals Ltd. 5,615.40 6,146.20 N.A. N.A.

Glenmark Pharmaceuticals Ltd. 8,682.50 10 0 ,554.5 10,31 0.90 10 .6 ,658

Hikal Ltd. 1,4 0 28.0 N.A. 1,8 0 54.8 N.A.

Intas Pharmaceuticals Ltd. N.A. N.A. N.A. N.A.

Jubilant life Sciences Ltd. 9,442.90 10,480.80 10,871.70 11,711.0

Lupin Ltd. 15 0 ,677.4 17 0 ,723.9 18 0 ,189.3 1 9,238.5

Morepen Laboratories Ltd. 602.1 N.A. 711.1 729.2

Nestle India Ltd. 1 7,630.50 19 0 ,631.0 19,633.2 20 .7 ,558

Panacea Biotec Ltd. 2,209.90 N.A. 1,551.60 N.A

Pfizer Ltd. 2,418.70 2,718.20 2,518.80 2,517.3


Piramal Healthcare Ltd. 4 ,350.00 4 ,775.80 5 ,518.30 6,194.4

Plethico Pharmaceuticals Ltd. 4,545.7 4,121.0 4,207.4 3,638.8

Ranbaxy Laboratories Ltd. 20,931.2 20,955.3 3 7,923.1 36,954.0

Strides Arcolab Ltd 5,812.50 7,693.10 6,864.7 5, 7 274.

Sun Pharmaceuticals Industries Ltd. 1 6,357.20 1 8,946.00 2 1,451.30 N.A.

Torrent Pharmaceuticals Ltd 6,133.9 6,833.3 6,965.9 6, 3 743.

Twilight Litaka Pharma Ltd. 1,835.60 N.A. 1,867.20 N.A.

Vimta Labs Ltd 2 45.438 20 3 2.42 2 01.515 N.A.

Vista Pharmaceuticals 11.461 N.A. 5.093 N.A.

Wockhardt Ltd. 10 0 ,532.1 11 0 ,105.3 12 0 ,086.7 12 .9 ,413

Zandu Realty Ltd. N.A. N.A. N.A. N.A.

Annual Financial Results – Income (INR mn)

Companies F Y ’09 F Y ’10 FY ’11 FY’ 12

Abott India Ltd. 775.1 753.0 1 ,203.9 1 ,415.3

Ajanta Pharma Ltd. 254.3 340 507.1 772.7

Alembic Ltd. 108.17 395.378 ‐ 129.019 1,301.4

Amrutanjan Health Care Ltd. 923.9 4 114.72 102.12 127.10

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9

Cipla Ltd. 7,710.20 10,825.90 9,895.70 N.A.



Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0

Divi's Laboratories Ltd. 4,166.40 3,403.40 4,292.70 5,332.6

Dr. Reddy’s Laboratories (DRL) ‐5,168.00 1,068.00 11,040.00 14,262.1

Elder Pharmaceuticals Ltd. 608.3 495.0 642.2 759.6

FDC Ltd. 862.1 1,491.30 1,508.90 N.A.

Fresenius Kabi Oncology Ltd. ‐1,460.20 ‐333.6 160.1 N.A.

Glaxosmithkline Consumer Healthcare Ltd. 2,327.8 2,998.5 3,552.1 3,765.6

GlaxoSmithKline Pharmaceuticals Ltd. 5,078.60 5,605.70 4,285.9 N.A.

Glenmark Pharmaceuticals Ltd. 1,916.60 3,244.70 4,532.10 4,603.5

Hikal Ltd. 405 72.9 370.2 460.4

Intas Pharmaceuticals Ltd. 923.2 2,058.20 2,079.7 N.A.

Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Morepen Laboratories Ltd. ‐417.6 ‐62.2 ‐469.4 ‐236.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7

Panacea Biotec Ltd. ‐654.8 817.2 1,446.70 ‐2,056.5

Pfizer Ltd. 1,371.2* N.A. 1,697.60 1,846.1


Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0

Plethico Pharmaceuticals Ltd. 2,169.30 2,444.00 1,029.1 951.1

Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Strides Arcolab Ltd 1,096.80 1,224.50 2,244.8 8,258.4

Sun Pharmaceuticals Industries Ltd.

18,177.30 13,510.80 18,160.60 25,872.5

Torrent Pharmaceuticals Ltd 1,843.70 2,312.00 2,701.70 2,840.4

Twilight Litaka Pharma Ltd. 219.4 326.3 512.5 515.4

Vimta Labs Ltd 40.443 26.586 ‐46.651 ‐119.99

Vista Pharmaceuticals ‐9.616 ‐13.502 ‐2.922 N.A.

Wockhardt Ltd. ‐4,355.4*' ‐9,804.20 905.2 3,427.1

Zandu Realty Ltd. 152.549 13.906 9.144 17.67

Companies AprJun 2011

JulSep 2011

OctDec 2011

JanM 012 ar 2

Abott India Ltd. 171.0 436.3 368.8 270.8

Ajanta Pharma Ltd. 125.3 N.A. 185.1 343.7

Alembic Pharmaceuticals Ltd. 275.6 380.4 442.3 203.1

Amrutanjan Health Care Ltd. N.A. N.A. 43.17 N.A

Quarterly Financial Results – Income (INR mn)


Biocon Ltd. 700.5 857.0 848.50 978.0

Cadila Healthcare Ltd. 2,298.20 1,0 0 26.8 1,492.10 1,708.8

Cipla Ltd. 2 ,533.40 N.A. 2 ,699.10 N.A.

Claris Lifesciences Ltd. 377.2 340.1 346.3 216.9

Dabur India Ltd. 1,277.4 1,738.6 1,728.20 1,705.0

Divi's Laboratories Ltd. 1,025.90 N.A. 1,225.50 2 ,169.10

Dr. Reddy’s Laboratories (DRL) 2 ,627.00 3 ,078.00 5 ,130.00 3 ,427.0

Elder Pharmaceuticals Ltd. 201.2 193.5 182.9 142.9

FDC Ltd. 344 N.A. 329 N.A.

Fresenius Kabi Oncology Ltd. N.A. N.A. 14 N.A.

Glaxosmithkline Consumer Healthcare Ltd. 824.6 1,030.3 591.0 1,319.7

GlaxoSmithKline Pharmaceuticals Ltd. 1,475.40 1 ,458.60 N.A. N.A.

Glenmark Pharmaceuticals Ltd. 2,1 0 01.1 558.6 4 61.20 1,503.6

Hikal Ltd. 145 N.A. 130.4 N.A.

Intas Pharmaceuticals Ltd. N.A. N.A. N.A. N.A.

Jubilant life Sciences Ltd. 771.2 793.6 ‐783.90 635.3

Lupin Ltd. 2 ,100.80 2,6 0 68.7 2, 0 350.6 1,556.4

Morepen Laboratories Ltd. ‐131.3 N.A. ‐90.6 68.1

Nestle India 2 ,138.30 2,6 0 11.8 2 ,308.30 2,757.3

Panacea Biotec Ltd. 167.2 N.A. ‐717.2 N.A.

Pfizer Ltd. 412.4 469.9 482.8 481.0

Piramal Healthcare Ltd. 892.3 524.3 85.2 386.8

Plethico Pharmaceuticals Ltd. 743.6 385.9 ‐652.8 474.4


Ranbaxy Laboratories Ltd. 2 ,432.4 ‐4 ,645.8 ‐2 7 9,827. 1 2,467.6

Strides Arcolab Ltd 688.9 464.7 684.1 6,420.7

Sun Pharmaceuticals Industries Ltd. 5,010.0 5 ,977.4 6 ,683.0 N.A.

Torrent Pharmaceuticals Ltd 1 ,025.20 999.9 831.8 ‐16.5

Twilight Litaka Pharma Ltd. 128.2 N.A. 93.8 N.A.

Vimta Labs Ltd ‐14.4 38 ‐3 3 3.97 ‐ 37.702 N.A.

Vista Pharmaceuticals ‐2.687 N.A. 4.488 N.A.

Wockhardt Ltd. 1 ,939.60 1 ,275.80 2 ,128.10 ‐1,916.4

Zandu Realty Ltd. 1.931 3.205 11.68 N.A.

* denotes a change in financial year

Events Calendar

India Healthcare Congress 2012

Date: 5

th JVenue: Gr

une – 6th June 2012 and harashtra

Website: Hyatt Mumbai, Ma

www.indiahealthcarecongress.in Contact No.: +91‐40‐40404160


Research on India (ROI) is a leading source for market research on various sectors in ndia that offers premium research content from worldwide publishers of market

orts. Iresearch rep Contact us:

mW: https://www.researchonindia.co ; International: +91 (33) 4027 6214/5 T

E: India (Toll Free): 1800 102 1133: [email protected] Connect with Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.


http://www.facebook.com/researchonindia

https://twitter.com/ResearchOnIndia

http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

Documents

Research on India_Healthcare Sector in India Monthly Update_May 2012